Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target

Author： Macphee Colin   Benson G Martin   Shi Yi   Zalewski Andrew  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.6, 2005-06, pp. : 671-679

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lipoprotein-Associated Phospholipase A2: How Effective as a Risk Marker of Cardiovascular Disease and as a Therapeutic Target?

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 10, Iss. 4, 2011-01 ,pp. : 236-246

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Modulation of Lipoprotein-associated Phospholipase A2 (Lp-PLA2)

By  

Current Pharmaceutical Design, Vol. 17, Iss. 33, 2011-11 ,pp. : 3656-3661

Bentham Science Publishers

Access to resources Recommend Favorite

Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque

By Macphee Colin H   Suckling Keith E  

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 3, 2002-06 ,pp. : 309-314

Informa Healthcare

Access to resources Recommend Favorite

Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease

By  

Current Pharmaceutical Design, Vol. 24, Iss. 3, 2018-04 ,pp. : 291-296

Bentham Science Publishers

Access to resources Recommend Favorite

High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease

By  

Current Pharmaceutical Design, Vol. 16, Iss. 13, 2010-05 ,pp. : 1480-1493

Bentham Science Publishers

Access to resources Recommend Favorite